{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/chickenpox/how-up-to-date-is-this-topic/update/","result":{"pageContext":{"chapter":{"id":"5f0098ae-9d37-5658-9379-66477733f220","slug":"update","fullItemName":"Update","depth":2,"htmlHeader":"<!-- begin field 2501a3a4-84e7-4820-bc89-2c4ae93c9393 --><h2>Update</h2><!-- end field 2501a3a4-84e7-4820-bc89-2c4ae93c9393 -->","summary":null,"htmlStringContent":"<!-- begin item edf649e7-7a86-49d9-9574-5a831a13903b --><!-- end item edf649e7-7a86-49d9-9574-5a831a13903b -->","topic":{"id":"5d1b7a44-f7ff-52e9-a218-c53ecadb0e4c","topicId":"4960f8a4-0140-4c3b-9bd0-b1ac6fccd648","topicName":"Chickenpox","slug":"chickenpox","lastRevised":"Last revised in August 2018","chapters":[{"id":"fe0450ab-ddfd-5960-bb47-b986d9cc6059","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"ff90f80f-13d4-5732-8d09-9c5566ce6ec2","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"16ae9969-1384-5b7b-aff0-1ac19aeee530","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"10059b43-4a23-59cf-8f5f-31f8d5e8e3c9","slug":"changes","fullItemName":"Changes"},{"id":"5f0098ae-9d37-5658-9379-66477733f220","slug":"update","fullItemName":"Update"}]},{"id":"9d70228e-0283-5d34-a4af-5237097d0a02","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"fa1d46ea-9d63-5d1a-b60c-9b96e87f802c","slug":"goals","fullItemName":"Goals"},{"id":"4e21e939-92fd-555c-a175-93b8a626169a","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"ea18d1e8-0bdd-542f-a985-2952ecabca2d","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"5d911096-5b50-551b-a17a-cff3070315b0","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"601f7c68-386e-5474-96f1-d6239bd81750","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"305e8fa8-8eb6-5b69-a902-93019e0c2c17","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"bb9b11dc-3295-5e2b-9798-37bb8b6ebbc0","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"145f102c-4e0f-52c9-8b3b-e0b5c6eb112e","slug":"definition","fullItemName":"Definition"},{"id":"9f4d0cad-78a8-568f-831e-8878d2f4bfd3","slug":"transmission","fullItemName":"Transmission"},{"id":"5691920a-f618-5a98-ab32-417dfc782db1","slug":"prevalence","fullItemName":"Prevalence"},{"id":"eb6a66b5-2006-5968-a97d-52de72842cbf","slug":"complications","fullItemName":"Complications"}]},{"id":"a3eb8e9b-cdd9-5243-8353-09aac3fdc322","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"ff9f70a8-0c29-5357-946d-bbca67eafbbf","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"b651c5b4-34df-5480-b05d-909c9023a7a5","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"3844af91-e26b-515e-a645-9725d2f54810","fullItemName":"Management","slug":"management","subChapters":[{"id":"7700c175-994a-51d5-a2d0-36eb7478e2c1","slug":"child-or-adult","fullItemName":"Scenario: Child or adult"},{"id":"f6a62aa2-354d-5eee-a868-fb5d162115ef","slug":"pregnant-woman","fullItemName":"Scenario: Pregnant woman"},{"id":"c659257f-8875-5440-ae24-57c071cf226c","slug":"breastfeeding-woman","fullItemName":"Scenario: Breastfeeding woman"},{"id":"499e6045-af39-5bc4-952b-edcb6b29144f","slug":"neonate","fullItemName":"Scenario: Neonate"},{"id":"dac00668-b032-569c-8b5a-260c2f1625b3","slug":"immunocompromised","fullItemName":"Scenario: Immunocompromised"},{"id":"072ae3a5-9cf4-5233-bca1-2d46e53de42b","slug":"exposure-to-chickenpox","fullItemName":"Scenario: Exposure to chickenpox"}]},{"id":"fa12b54d-0c95-5ee8-8884-219ac7a9dd2a","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"a2d64426-afb7-5590-998d-3ed0d13b78d2","slug":"chlorphenamine","fullItemName":"Chlorphenamine"},{"id":"17d5cf92-3449-52d5-932c-f1b770061787","slug":"aciclovir","fullItemName":"Aciclovir"}]},{"id":"95550d9e-6be2-5a94-924a-c4c2f8e7dbe4","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"880099bb-bff8-543e-a1e8-267413ef45b9","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"c80905f1-b771-5170-8be8-c1bcee935552","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"6bf66548-b486-53e1-bce7-d9bb45af9bea","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"52168b40-dab0-5afb-9662-bb28014b5734","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"5fa2da47-e83a-5886-9c1b-c6ae4e97a0a7","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"769ea126-78ac-540c-a1c9-38446d44e22e","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"87e1772a-0cd8-5e0c-ad7a-b676a65171bb","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"16ae9969-1384-5b7b-aff0-1ac19aeee530","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"edf42e8f-f56e-5bf3-8e01-18f1d66a8448","slug":"new-evidence","fullItemName":"New evidence","depth":3,"htmlHeader":"<!-- begin field 38e7e093-7532-4bcf-aa70-b60c4e13eaf2 --><h3>New evidence</h3><!-- end field 38e7e093-7532-4bcf-aa70-b60c4e13eaf2 -->","summary":null,"htmlStringContent":"<!-- begin item 83900df7-adc3-4f61-9892-0ed360687efa --><!-- begin field c79c33cb-1957-43ec-9deb-367d1be5bd84 --><h3>Evidence-based guidelines</h3><!-- end field c79c33cb-1957-43ec-9deb-367d1be5bd84 --><!-- begin field 452ec099-715c-4d66-b2d7-8e331e824ea4 --><ul><li>PHE (2017) Immunoglobulin: when to use. Public Health England. <a href=\"http://www.gov.uk/\" data-hyperlink-id=\"8fe01a24-41df-476a-be04-a95700e5122e\">www.gov.uk</a> [<a href=\"https://www.gov.uk/government/publications/immunoglobulin-when-to-use\" data-hyperlink-id=\"99559e1d-f5d3-4616-a1df-a95700e5123a\">Free Full-text</a>]</li></ul><!-- end field 452ec099-715c-4d66-b2d7-8e331e824ea4 --><!-- begin field 2007ede2-1d1a-47c0-a2ac-b90d2aade1ed --><h3>HTAs (Health Technology Assessments)</h3><!-- end field 2007ede2-1d1a-47c0-a2ac-b90d2aade1ed --><!-- begin field 86a98378-06aa-4dfb-9c04-fabdcea88a05 --><p>No new HTAs since 1 September 2016.</p><!-- end field 86a98378-06aa-4dfb-9c04-fabdcea88a05 --><!-- begin field b3d1146f-cc41-44a5-a539-f699f6cec08c --><h3>Economic appraisals</h3><!-- end field b3d1146f-cc41-44a5-a539-f699f6cec08c --><!-- begin field 0606fe83-5a02-4605-bf1b-b52fe2e881ee --><p>No new economic appraisals relevant to England since 1 September 2016.</p><!-- end field 0606fe83-5a02-4605-bf1b-b52fe2e881ee --><!-- begin field dcccd854-3403-4c0b-8a92-175bfb1bdf92 --><h3>Systematic reviews and meta-analyses</h3><!-- end field dcccd854-3403-4c0b-8a92-175bfb1bdf92 --><!-- begin field 37f671b8-95db-4e70-8757-8a4d9ac84c76 --><p>No new systematic reviews or meta-analyses since 1 September 2016.</p><!-- end field 37f671b8-95db-4e70-8757-8a4d9ac84c76 --><!-- begin field 0e9f3497-cfe0-461a-bd53-7afed62a2a0d --><h3>Primary evidence</h3><!-- end field 0e9f3497-cfe0-461a-bd53-7afed62a2a0d --><!-- begin field 97c52bc0-0c21-4c52-89e4-ac26ebb57f8a --><p>No new randomized controlled trials published in the major journals since 1 September 2016.</p><!-- end field 97c52bc0-0c21-4c52-89e4-ac26ebb57f8a --><!-- end item 83900df7-adc3-4f61-9892-0ed360687efa -->","subChapters":[]},{"id":"c66c7597-e931-52c1-bd71-ff282a7c25c9","slug":"new-policies","fullItemName":"New policies","depth":3,"htmlHeader":"<!-- begin field d4a0d961-f02c-463f-95c6-10273c88ba2e --><h3>New policies</h3><!-- end field d4a0d961-f02c-463f-95c6-10273c88ba2e -->","summary":null,"htmlStringContent":"<!-- begin item cf1135dc-14fb-495c-a084-e572603f01a3 --><!-- begin field 88576c63-4789-443e-b140-c7a1bfce22e5 --><p>No new national policies or guidelines since 1 September 2016.</p><!-- end field 88576c63-4789-443e-b140-c7a1bfce22e5 --><!-- end item cf1135dc-14fb-495c-a084-e572603f01a3 -->","subChapters":[]},{"id":"ab7dcb4a-fa73-5a28-afcf-ce8e1fa85286","slug":"new-safety-alerts","fullItemName":"New safety alerts","depth":3,"htmlHeader":"<!-- begin field b316635e-fb63-43cd-b47b-5f96e6639108 --><h3>New safety alerts</h3><!-- end field b316635e-fb63-43cd-b47b-5f96e6639108 -->","summary":null,"htmlStringContent":"<!-- begin item 08edebee-d60c-4aed-8691-99a81a0dff8d --><!-- begin field 12ce6ae2-056e-49c3-9048-4f0705a135c1 --><p>No new safety alerts since 1 September 2016.</p><!-- end field 12ce6ae2-056e-49c3-9048-4f0705a135c1 --><!-- end item 08edebee-d60c-4aed-8691-99a81a0dff8d -->","subChapters":[]},{"id":"152c8351-cfa3-517a-9f5b-7a94b81ce39e","slug":"changes-in-product-availability","fullItemName":"Changes in product availability","depth":3,"htmlHeader":"<!-- begin field fcd433e6-5f3a-4170-95e2-b2c4c5082dbf --><h3>Changes in product availability</h3><!-- end field fcd433e6-5f3a-4170-95e2-b2c4c5082dbf -->","summary":null,"htmlStringContent":"<!-- begin item 3e096d56-36aa-48ae-8c1a-6f874180edfb --><!-- begin field 3bf920e6-36c7-43bf-81c5-4f610ea49497 --><ul><li>Varilrix is now licensed for active immunisation against varicella of healthy subjects from the age of 9 months. See <a href=\"http://www.medicines.org.uk/emc/medicine/9787\" data-hyperlink-id=\"349e4a63-9f85-4dc1-abb8-a95700e734b9\">http://www.medicines.org.uk/emc/medicine/9787</a>.</li></ul><!-- end field 3bf920e6-36c7-43bf-81c5-4f610ea49497 --><!-- end item 3e096d56-36aa-48ae-8c1a-6f874180edfb -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}